Oxurion Receives Transparency Notifications

More here:
Oxurion Receives Transparency Notifications

Initiated Phase 2 proof-of-concept study of RZ402

View original post here:
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

Continued here:
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

Montrouge, France, February 10, 2023

Read more from the original source:
DBV Technologies to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.

See the original post here:
Science 37 Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, responded today to the recent ruling by the Seoul Central District Court in favor of Medytox, Inc. related to a long-standing trade secret dispute between Medytox and Daewoong Pharmaceutical Co. Ltd. AEON stated that it does not expect the ruling will affect its ongoing clinical development or planned commercialization strategy for ABP-450 (prabotulinumtoxinA) injection in target markets.

Read the rest here:
AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong...

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10

Visit link:
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

Here is the original post:
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET

Read this article:
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of...

BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:

Read more:
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical.

See more here:
Invivyd Announces Changes to Executive Team

SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced that it has been issued a trademark for RECCE® by the Trade Marks Registry Intellectual Property Department in Hong Kong. This newly registered trademark strengthens the Company’s global intellectual property (IP) portfolio.

See more here:
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.

See the rest here:
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Additional Capital Will Help Fund Development of PAX-101

See the original post:
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET

See the original post:
MDxHealth Announces Pricing of Offering of ADSs in the United States

Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference

Read the original here:
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accordance with French regulatory requirements, is supplementing its previous announcement of the pricing of its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representing the right to receive one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”), which launched and priced on February 2, 2023, at a price to the public of $2.50 per ADS as announced on February 2, 2023. The closing of the Global Offering is expected to occur on or about February 7, 2023, subject to customary closing conditions.

Read the original here:
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

Bagsværd, Denmark, 3 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Go here to see the original:
Trading in Novo Nordisk shares by board members, executives and associated persons

Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco. Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco.

View post:
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

VALNEVA

Read the original here:
VALNEVA Declaration of shares and voting rights - January 31, 2023